Humanigen declares win in severe Covid-19, delivering much-needed pandemic weapon and vaulting ahead on post-Shkreli turnaround
Humanigen, the one-time Martin Shkreli-run biotech, announced that its antibody helped keep patients with Covid-19 off ventilation in a Phase III trial, potentially giving doctors just their second proven tool for helping patients with severe disease.
Humanigen said that in the 520-person, placebo-controlled study, the drug lenzilumab improved the odds of ventilator-free survival by 54%. In the placebo arm, 22.1% of patients either died or went on a ventilator within 28 days of treatment. In the drug arm, only 15.6% did.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.